Spots Global Cancer Trial Database for melanoma of unknown primary

Every month we try and update this database with for melanoma of unknown primary cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases	NCT05341349	Clinical Stage ... Melanoma of Unk... Metastatic Mali... Metastatic Mela... Metastatic Muco... Metastatic Ocul... Pathologic Stag...	Ipilimumab Nivolumab Pembrolizumab Stereotactic Ra... Tumor Treating ...	22 Years -	Emory University
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma	NCT03033576	Clinical Stage ... Clinical Stage ... Melanoma of Unk... Mucosal Melanom... Unresectable Cu... Unresectable Me...	Ipilimumab Nivolumab	18 Years -	National Cancer Institute (NCI)
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases	NCT02858869	Metastatic Mali... Metastatic Mela... Mucosal Melanom... Ocular Melanoma Stage IV Non-Sm... Stage IV Skin M... Melanoma of Unk...	Pembrolizumab Stereotactic Ra...	18 Years -	Emory University
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases	NCT05341349	Clinical Stage ... Melanoma of Unk... Metastatic Mali... Metastatic Mela... Metastatic Muco... Metastatic Ocul... Pathologic Stag...	Ipilimumab Nivolumab Pembrolizumab Stereotactic Ra... Tumor Treating ...	22 Years -	Emory University
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement	NCT04221438	Melanoma of Unk... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Cutan...	Binimetinib Computed Tomogr... Conventional Su... Encorafenib Fluorothymidine... Positron Emissi...	18 Years -	Eastern Cooperative Oncology Group
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement	NCT04221438	Melanoma of Unk... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Cutan...	Binimetinib Computed Tomogr... Conventional Su... Encorafenib Fluorothymidine... Positron Emissi...	18 Years -	Eastern Cooperative Oncology Group
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery	NCT01274338	Melanoma of Unk... Recurrent Melan... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Ipilimumab Quality-of-Life... Recombinant Int...	12 Years -	National Cancer Institute (NCI)
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery	NCT01274338	Melanoma of Unk... Recurrent Melan... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Ipilimumab Quality-of-Life... Recombinant Int...	12 Years -	National Cancer Institute (NCI)
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy in Patients With Operable Melanoma	NCT04708418	Clinical Stage ... Melanoma of Unk... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Cutan...	Biopsy Biospecimen Col... Computed Tomogr... Pembrolizumab Positron Emissi... Surgical Proced... VLP-encapsulate...	18 Years -	National Cancer Institute (NCI)
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial	NCT04462406	Advanced Melano... Clinical Stage ... Clinical Stage ... Melanoma of Unk... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Ac... Unresectable Me... Unresectable Mu...	Ipilimumab Nivolumab Patient Observa... Pembrolizumab	18 Years -	Eastern Cooperative Oncology Group
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial	NCT04462406	Advanced Melano... Clinical Stage ... Clinical Stage ... Melanoma of Unk... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Ac... Unresectable Me... Unresectable Mu...	Ipilimumab Nivolumab Patient Observa... Pembrolizumab	18 Years -	Eastern Cooperative Oncology Group

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: